Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000120

EU PAS number

EUPAS1000000120

Study ID

1000000120

Official title and acronym

DARWIN EU® – Frailty and polypharmacy among adults with selected cancers at the time of diagnosis

DARWIN EU® study

Yes

Study countries

Belgium
Estonia
Germany
Netherlands
Spain
United Kingdom

Study description

This study intends to investigate the ability to characterise frailty and polypharmacy in real-world data sources, to estimate the prevalence of frailty and polypharmacy in people aged 18 and above with selected cancers at the point of diagnosis and to describe their characteristics. While the focus is on older adults, the study will explore the full age range of adulthood to better contextualise the results.

Study status

Planned
Research institution and networks

Institutions

IQVIA
United Kingdom
First published:
22/04/2024
Institution
Non-Pharmaceutical companyENCePP partner
University of Oxford, University of Tartu

Networks

Contact details

Talita Duarte-Salles

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Data collection

Planned:

Date of final study report

Planned:
Sources of funding
EMA
Study protocol
Initial protocol

DARWIN_EU_D2.2.3_Protocol_P2-C1-009_Frailty and Polypharmacy at cancer diagnosis_v2.3.pdf

English (1.58 MB - PDF)View document
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable